Novo Nordisk A/S (CPH: NOVO.B)
Denmark
· Delayed Price · Currency is DKK | Market Cap | 4.16T |
| Revenue (ttm) | 258.00B |
| Net Income (ttm) | 89.90B |
| Shares Out | 4.43B |
| EPS (ttm) | 20.08 |
| PE Ratio | 46.71 |
| Forward PE | 36.53 |
| Dividend | 9.40 (1.02%) |
| Ex-Dividend Date | Aug 15, 2024 |
| Volume | 3,889,823 |
| Open | 923.70 |
| Previous Close | 922.20 |
| Day's Range | 919.80 - 941.30 |
| 52-Week Range | 614.30 - 1,033.20 |
| Beta | 0.13 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 6, 2024 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2023, Novo Nordisk's revenue was 232.26 billion, an increase of 31.26% compared to the previous year's 176.95 billion. Earnings were 83.68 billion, an increase of 50.71%.
Financial StatementsNews
Ozempic: Unexpected Anti-Aging Miracle Drug? Researchers Reveal Surprising Potential
Researchers are now suggesting that a drug for Type 2 diabetes and obesity might actually have anti-aging powers . Harlan Krumholz of the Yale School of Medicine declared that semaglutide , marketed a...
These 3 Factors Could Make Eli Lilly Stock a Better Buy Than Novo Nordisk Right Now
This competitive showdown just saw one of the players hit a couple of bumps.
Novo highlights heart benefits of weight loss drug with new analysis
Novo Nordisk (NVO) posts new data to show the potential of its weight loss therapy semaglutide in reducing heart failure risk. Read more here.
This New Finding About Ozempic and Wegovy Could Hurt Novo Nordisk's Stock
The addressable market for the treatments could potentially contract significantly.
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 30 August 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated perso...
Catalent ends FY24 on a strong note ahead of Novo buyout
Catalent (CTLT) stock trades higher after beating Q4 forecasts months before the buyout from Novo Holdings, the parent of Novo Nordisk (NVO). Read more here.
Competitor Analysis: Evaluating Johnson & Johnson And Competitors In Pharmaceuticals Industry
In the fast-paced and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry com...
Catalent beats revenue estimates ahead of deal close with Novo Nordisk parent
Contract drug manufacturer Catalent beat analysts' estimates for fourth-quarter revenue on Thursday, helped by its biologics segment that develops and manufactures cell and gene therapies.
Comparing Merck & Co With Industry Competitors In Pharmaceuticals Industry
In today's rapidly changing and highly competitive business world, it is imperative for investors and industry observers to carefully assess companies before making investment choices. In this article...
Medicare coverage of Novo Nordisk's Wegovy could cost up to $145B annually
Use of Novo Nordisk's weight loss drug Wegovy for Medicare enrollees with obesity individuals and cardiovascular disease could cost up to $145B annually. Read more here.
Ozempic Could Have a Terrible Side Effect. Is Novo Nordisk in Trouble?
Shareholders don't have too much to fear -- yet.
Obesity drugs’ next wave: These companies could snag 20% of GLP-1 market, analysts say
While Eli Lilly and Novo Nordisk dominate the obesity-drug market, there’s a vast field of would-be competitors closing in behind them — and the most successful among those next-wave contenders stand ...
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 26 August 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council ...
Novo Nordisk Does Not Operate As Drug Cartel, CEO Defends US Pricing Of Ozempic Against Criticism Over High Drug Prices
Novo Nordisk A/S (NYSE: NVO) CEO Lars Fruergaard Jørgensen has defended the high U.S. prices of the company’s blockbuster drugs, Ozempic and Wegovy , stating that these medications are reducing the e...
NBC News Exclusive: Ozempic and Wegovy Novo Nordisk CEO speaks out on high prices, drug shortages
Blockbuster drugs Ozempic and Wegovy have sparked conversation and changed weight loss worldwide. In an exclusive interview, NBC News’ Megan Fitzgerald sits down with Novo Nordisk CEO Lars Fruergaard ...
Ozempic maker defends high U.S. price: It’s ‘helping’ reduce the cost of obesity
The CEO of Novo Nordisk is defending the high cost of Ozempic and Wegovy in America, saying the blockbuster drugs are ultimately saving taxpayers money on obesity-related costs.
Eli Lilly, Novo Nordisk to maintain 'two horse race' in GLP-1 weight loss market
Eli Lilly and Novo Nordisk dominate the GLP-1 receptor agonist market for weight loss, with little competition expected to challenge their stronghold. Read more here.
This GLP-1 Biotech Stock Could Give Novo Nordisk a Run for Its Money
Its GLP-1 medicines are just one reason why it could threaten Novo Nordisk.
Viking Rises 25% in a Month: Should You Buy or Wait?
Shares of Viking Therapeutics (NASDAQ: VKTX) have soared nearly 25% in the past month, all thanks to progress with its investigational obesity and non-alcoholic steatohepatitis (NASH) candidates, whi...
Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets
The recent move by the U.S. government to negotiate Medicare drug prices has triggered speculation about which drugs could be targeted in the next round of negotiations, which is set for 2027. Last we...
Ozempic on Wall Street's list for 2027 Medicare drug negotiations
Now that the U.S. government has negotiated prices for some Medicare program drugs effective in 2026, Wall Street analysts are betting on a 2027 list that will include Novo Nordisk's blockbuster Ozemp...
These Were the Top-Selling GLP-1 Drugs Last Quarter From Eli Lilly and Novo Nordisk
Ozempic remains on top in the GLP-1 drug market -- but for how long?
Forget Novo Nordisk: Buy This Magnificent Pharma Stock Instead
Vertex Pharmaceuticals has a lot going for it.
Novo Nordisk Vs. Eli Lilly: Beyond The Weight-Loss Drug Battle
The rivalry between Novo Nordisk A/S NVO and Eli Lilly and Co LLY has heated up as both companies vie for dominance in the booming obesity-drug market. But for investors, the real story may lie beyond...